Subject Predicate Object
hCVoNLjs
a
Resource
Government response
government response summary
Current BRCA testing is provided in accordance with a published clinical commissioning policy which is in line with NICE clinical guidelines. The policy has no age criteria.
government response details
We are sorry to hear of anybody affected by ovarian cancer. In Achieving World Class Cancer Outcomes: A Strategy for England 2015-2020 (1), the independent Cancer Taskforce noted that faulty BRCA genes are rare. However, between 45 and 90 per cent of women with a mutated BRCA1 or BRCA2 gene will develop breast cancer during their lifetime. NHS England currently commissions Medical Genetics Services to provide BRCA testing in accordance with a published clinical commissioning policy which is in line with current National Institute for Health and Care Excellence clinical guidelines that address the needs of this group. The policy has no age criteria so the test is already available to women aged 30 and over.https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e01pb-brca-ovarian-cancer-oct15.pdf In addition, between 40 and 60 per cent of women with a faulty BRCA1 gene, and between 10 and 30 per cent with a faulty BRCA2 gene, will develop ovarian cancer at some point in their lives. Testing women at the point of diagnosis can ensure access to the most relevant treatment and enable family members to understand their own risk and take preventative action where appropriate. This may include more regular screening, use of chemo-preventive agents such as tamoxifen, or other measures. Recommendation 36 of the cancer strategy states: NHS commissioners should ensure that:• All women with non-mucinous epithelial ovarian cancer are offered testing for BRCA1/BRCA2 at the point of diagnosis• All women under the age of 50 diagnosed with breast cancer are offered testing for BRCA1/BRCA2 at the point of diagnosisThese tests will enable any family members at high risk to be identified and active surveillance programmes put in place. Where applicable, positive tests should guide decisions on the most clinically and cost-effective prevention interventions or treatments.NHS England is leading the health and care system in implementing the recommendations in the cancer strategy.(1) http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdfDepartment of Health and Social Care
government response created at
2018-06-11T15:17:25.741000+00:00
government response updated at
2018-06-11T15:17:25.741000+00:00
government response has e-petition
Z9SQb7KX
Z9SQb7KX
e-petition has government response
hCVoNLjs